After years of development, significant progress has been made in the research and development of anti-tumor drugs. However, in the face of solid tumors, which pose the most serious threat to human life and health and account for over 90% of malignant tumors, there is still a lack of efficient and highly specific drugs. This reflects the difficulty of developing anti-tumor drugs, and also means that the development of anti-tumor drugs requires the application of new concepts, technologies, and methods.
The progress of anti-tumor drugs meets the requirements of anti-tumor drug research and development, laying the foundation for personalized treatment and indicating a new era in anti-tumor drug research and development: molecular targeted drugs have improved the efficacy of some chemotherapy resistant tumors, and also have certain advantages in tolerance. The combination with chemotherapy, radiotherapy, and targeted drugs is expected to further improve efficacy. This research concept has permeated into various fields of anti-tumor drug development worldwide, laying the foundation for providing highly selective, efficient, and low toxicity drugs. At the same time, the research on biomarkers is increasingly valued, which not only contributes to the therapeutic application of anti-tumor drugs, but also promotes the in-depth development of anti-tumor drug research. In addition, the development of new therapeutic drugs such as anti-tumor vaccines has further enriched the treatment methods.
